No information is available on the clinical use of capivasertib during breastfeeding. Because of its potential toxicity in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during capivasertib therapy. With a half-life of 8.3 hours the drug should be cleared from the maternal bloodstream in 2 days. However, capivasertib is used in combination with fulvestrant, which may increase the risk to the infant.
